Jonathan Aschoff
Stock Analyst at Roth Capital
(0.48)
# 4,163
Out of 5,090 analysts
39
Total ratings
24.49%
Success rate
-35.06%
Average return
Main Sectors:
Stocks Rated by Jonathan Aschoff
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PTHS Pelthos Therapeutics | Initiates: Buy | $57 | $26.57 | +114.53% | 1 | Nov 25, 2025 | |
| GTBP GT Biopharma | Initiates: Buy | $11 | $0.61 | +1,705.05% | 1 | Dec 2, 2024 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $19 → $21 | $8.71 | +141.10% | 2 | Sep 24, 2024 | |
| APVO Aptevo Therapeutics | Maintains: Buy | $11,100 → $5,920 | $1.35 | +438,418.52% | 3 | Sep 23, 2024 | |
| BRTX BioRestorative Therapies | Maintains: Buy | $15 → $18 | $1.11 | +1,521.62% | 4 | Aug 14, 2024 | |
| NUWE Nuwellis | Reiterates: Buy | $714 | $2.43 | +29,282.72% | 2 | Aug 13, 2024 | |
| GOVX GeoVax Labs | Initiates: Buy | $20 | $0.38 | +5,203.63% | 1 | Jul 16, 2024 | |
| MBRX Moleculin Biotech | Maintains: Buy | $1,000 | $7.24 | +13,712.15% | 2 | Apr 12, 2024 | |
| CLRB Cellectar Biosciences | Maintains: Buy | $600 → $840 | $3.77 | +22,181.17% | 4 | Mar 28, 2024 | |
| MNMD Mind Medicine (MindMed) | Maintains: Buy | $25 → $36 | $12.35 | +191.50% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3,750 → $18,000 | $3.86 | +466,221.24% | 2 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $9.65 | +210.88% | 3 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $200 | $5.77 | +3,366.20% | 1 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $14 | $5.56 | +151.80% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7,200 → $21,600 | $1.04 | +2,086,856.52% | 2 | Feb 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $8 | $1.22 | +555.74% | 1 | Jun 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $100 | $2.34 | +4,173.50% | 1 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $400 | $0.84 | +47,769.79% | 1 | Nov 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $38 | $8.03 | +373.23% | 1 | Mar 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $96 | $2.07 | +4,537.68% | 3 | Nov 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $1.91 | +580.63% | 1 | Dec 19, 2019 |
Pelthos Therapeutics
Nov 25, 2025
Initiates: Buy
Price Target: $57
Current: $26.57
Upside: +114.53%
GT Biopharma
Dec 2, 2024
Initiates: Buy
Price Target: $11
Current: $0.61
Upside: +1,705.05%
Zevra Therapeutics
Sep 24, 2024
Maintains: Buy
Price Target: $19 → $21
Current: $8.71
Upside: +141.10%
Aptevo Therapeutics
Sep 23, 2024
Maintains: Buy
Price Target: $11,100 → $5,920
Current: $1.35
Upside: +438,418.52%
BioRestorative Therapies
Aug 14, 2024
Maintains: Buy
Price Target: $15 → $18
Current: $1.11
Upside: +1,521.62%
Nuwellis
Aug 13, 2024
Reiterates: Buy
Price Target: $714
Current: $2.43
Upside: +29,282.72%
GeoVax Labs
Jul 16, 2024
Initiates: Buy
Price Target: $20
Current: $0.38
Upside: +5,203.63%
Moleculin Biotech
Apr 12, 2024
Maintains: Buy
Price Target: $1,000
Current: $7.24
Upside: +13,712.15%
Cellectar Biosciences
Mar 28, 2024
Maintains: Buy
Price Target: $600 → $840
Current: $3.77
Upside: +22,181.17%
Mind Medicine (MindMed)
Mar 7, 2024
Maintains: Buy
Price Target: $25 → $36
Current: $12.35
Upside: +191.50%
Mar 5, 2024
Maintains: Buy
Price Target: $3,750 → $18,000
Current: $3.86
Upside: +466,221.24%
Feb 20, 2024
Reiterates: Buy
Price Target: $30
Current: $9.65
Upside: +210.88%
Aug 29, 2023
Reiterates: Buy
Price Target: $200
Current: $5.77
Upside: +3,366.20%
Aug 14, 2023
Reiterates: Buy
Price Target: $14
Current: $5.56
Upside: +151.80%
Feb 14, 2023
Maintains: Buy
Price Target: $7,200 → $21,600
Current: $1.04
Upside: +2,086,856.52%
Jun 15, 2022
Reinstates: Buy
Price Target: $8
Current: $1.22
Upside: +555.74%
Feb 25, 2022
Initiates: Buy
Price Target: $100
Current: $2.34
Upside: +4,173.50%
Nov 24, 2021
Initiates: Buy
Price Target: $400
Current: $0.84
Upside: +47,769.79%
Mar 11, 2021
Initiates: Buy
Price Target: $38
Current: $8.03
Upside: +373.23%
Nov 17, 2020
Downgrades: Sell
Price Target: $96
Current: $2.07
Upside: +4,537.68%
Dec 19, 2019
Initiates: Buy
Price Target: $13
Current: $1.91
Upside: +580.63%